Media Contact:
Paula Flavin
Project/Marketing Manager
D: 816-912-2000
Email: info@felixvet.com
Felixvet Receives FDA Approval for Methimazole Coated Tablets
Kansas City, MO — September 19, 2025 — Felixvet Inc. has received the first FDA generic approval for Methimazole Coated Tablets, an antithyroid drug indicated for the treatment of hyperthyroidism in cats. With this milestone, Felixvet continues to advance its mission of offering high-quality, affordable medications for companion animals. The company established its North American headquarters in Kansas City, Missouri, in 2023 and aims to serve veterinarians, pet owners and distributors alike.
The U.S. Food and Drug Administration approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole (NADA 141-292), originally approved in 2009. The approval followed a rigorous review of the drug’s safety and manufacturing quality.
“Felixvet is committed to meeting the clinical needs of veterinarians while offering affordable, reliable alternatives,” said Vince Palasota, President of North America at Felixvet. “Each of our products is developed to the highest regulatory standards to ensure consistency, quality and therapeutic equivalence.”
Hyperthyroidism is most commonly diagnosed in senior felines and results from an overproduction of thyroid hormones that may cause symptoms such as weight loss, increased thirst and urination, vomiting and hyperactivity. Methimazole Coated Tablets help manage this disease by inhibiting the synthesis of thyroid hormones.
Methimazole Coated Tablets are film-coated, which can aid in administration, and are supplied in 2.5 mg and 5 mg strengths for oral use. They are administered every 12 hours with dosage adjustments made in 2.5 mg increments, based on a cat’s response and veterinary guidance.
“Methimazole is an important therapy for managing feline hyperthyroidism, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”
Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.
For more information, email info@felixvet.com.
About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.